Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: Systemic availability

Brazilian Journal of Medical and Biological Research

Volumn 31, Issue 5, 1998, Pages 691-696

  Mansur, A P ^a   Avakian, S D ^a   Paula, R S ^a   Donzella, H ^a   Santos, S R C J ^a   Ramires, J A F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Arterial hypertension; Pharmacodynamics; Pharmacokinetics; Propranolol; Sublingual vs peroral administration

Indexed keywords

PROPRANOLOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HEMODYNAMIC MONITORING; HUMAN; HYPERTENSION; LIVER METABOLISM; MALE; ORAL DRUG ADMINISTRATION; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; SUBLINGUAL DRUG ADMINISTRATION;

EID: 0031802975     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X1998000500014     Document Type: Article

References (32)

1. Conolly ME, Kersting F & Dollerv CT (1976). The clinical pharmacology of beta-adrenoceptor blocking drugs. Progress of Cardiovascular Diseases, 19: 203-234.
2. Frishman WH (1981). ß-Adrenoceptor antagonists: new drugs and new indications. New England Journal of Medicine, 305: 500-506.
3. Watanabe AG (1983). Recent advances in knowledge about beta-adrenergic receptors: Application to clinical cardiology. Journal of the American College of Cardiology, 1: 82-89.
4. Wood AJJ, Carr K, Vestal RE, Belcher S, Wilkinson GR & Shand DG (1978). Direct measurement of propranolol bioavailability during accumulation to steady state. British Journal of Clinical Pharmacology, 6: 345-350.
5. Chidsey CA, Marselli P, Bianchetti G, Morganti A, Leonetti G & Zanchetti A (1975). Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation, 52: 313-318
6. Cid E, Mella F, Lucchini L, Carcamo M & Monasterio J (1986). Plasma concentrations and bioavailability of propranolol by oral, rectal and intravenous administration in man. Biopharmaceutics and Drug Disposition, 7: 559-566.
7. Landau AJ, Frishman WH, Alturk N, Adjei-Poku M, Fornasier-Bongo M & Furia S (1993). Improvement in exercise tolerance and immediate beta-adrenergic blockage with intranasal propranolol in patients with angina pectoris. American Journal of Cardiology, 72: 995-998.
8. Mansur AP, Ramires JAF, Avakian SD, Paula RS & Pileggi F (1991). Efeito comparative do diazepam, nifedipina, propranolol e da associação nifedipina e propranolol, por via sublingual, em pacientes com crise hipertensiva. Arquivos Brasileiros de Cardiologia, 57: 313-317.
9. Rao PS, Quesada LC & Mueller HS (1978). A simple micromethod for simultaneous determination of plasma propranolol and 4-hydroxy-propranolol. Clinica Chimica Acta, 88: 355-361.
10. Ritschel WA (1986). Handbook of Basic Pharmacokinetics. 3rd edn. Drug Intelligence Publications, Bethesda.
11. Shargel L & Yu ABC (1993). Applied Biopharmaceutics and Pharmacokinetics. 3rd edn. Prentice-Hall International Inc., New York.
12. Johnsson G & Regardh C-G (1976). Clinical pharmacokinetics of beta-adrenoceptor blocking drugs. Clinical Pharmacokinetics, 1: 233-263.
13. Beckett AH & Triggs EJ (1967). Buccal absorption of basic drugs and its application as an in vivo model of passive drug transfer through lipid membranes. Journal of Pharmacy and Pharmacology, 19 (Suppl S): S-31-S-41.
14. Mahajan P, Grech ED, Pearson RM, Ridgway EJ & Turner P (1984). Propranolol concentrations in blood serum, seminal plasma and saliva in man after a single oral dose. British Journal of Clinical Pharmacology, 18: 849-852.
15. Melander A, Danielson K, Schersten B & Wahlin E (1977). Enhancement of the bioavailability of propranolol and metoprolol by food. Clinical Pharmacology and Therapeutics. 22: 108-112.
16. Calhoun DA & Oparil S (1990). Treatment of hypertensive crisis. New England Journal of Medicine, 323: 1177-1183.
17. The 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (1988). Archives of Internal Medicine, 148: 1023-1038.
18. Braunwald E, Muller JE, Kloner RA & Maroko PR (1983). Role of beta-adrenergic blockage in the therapy of patients with myocardial infarction. American Journal of Medicine, 74: 113-123.
19. Frishman WH (1983). Multifactorial actions of beta-adrenergic blocking drugs in ischemic heart disease: current concepts. Circulation, 67 (Suppl I): I-11-I-18.
20. Holford NHG & Sheiner LB (1981). Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clinical Pharmacokinetics, 6: 429-453.
21. Frishman WH, Furberg CD & Friedewald WT (1984). ß-Adrenergic blockage for survivors of acute myocardial infarction. New England Journal of Medicine, 310: 830-837.
22. McDevitt DG (1979). Adrenoceptor blocking drugs: Clinical pharmacology and therapeutic use. Drugs, 17: 267-288.
23. Walle T, Webb JG, Bagwell EE, Walle UK, Daniell HB & Gaffney TE (1988). Stereo-selective delivery and actions of beta receptor antagonists. Biochemical Pharmacology, 37: 115-124.
24. Coltart DJ, Gibson DG & Shand DG (1971). Plasma propranolol levels associated with suppression of ventricular ectopic beats. British Medical Journal, 1: 490-491.
25. Frishman WH (1982). The beta-adrenoceptor blocking drugs. International Journal of Cardiology, 2: 165-178.
26. Coltart DJ & Shand DG (1970). Propranolol levels in the quantitative assessment of ß-adrenergic blockage in man. British Medical Journal, 3: 731-734.
27. Frohlich ED, Tarazi RC, Dustan HP & Page IH (1968). The paradox of beta-adrenergic blockage in hypertension. Circulation, 37: 417-423.
28. Shand DG, Nuckolls EM & Dates JA (1970). Plasma propranolol levels in adults with observation in four children. Clinical Pharmacology and Therapeutics, 11: 112-120.
29. Lennard MS, Jackson PR, Freestone S, Tucker GT, Ramsay LE & Woods HF (1984). The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. British Journal of Clinical Pharmacology, 17: 679-685.
30. Bowman SL, Hudson SA, Simpson G, Munro JF & Clements JA (1986). A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. British Journal of Clinical Pharmacology, 21: 529-532.
31. Poirier JM, LeJeunne C, Cheymol G, Cohen A, Barre J & Hughes FC (1990). Comparison of propranolol and sotalol pharmacokinetics in obese subjects. Journal of Pharmacy and Pharmacology, 42: 344-348.
32. Cheymol G, Poirier J-M, Barre J, Pradalier A & Dry J (1987). Comparative pharmacokinetics of intravenous propranolol in obese and normat volunteers. Journal of Clinical Pharmacology, 27: 874-879.